Calculate Your Salary Ranking
Home > Adherex Technologies Salary

Adherex Technologies Salary
  • 45
  • 81
  • 53

Adherex Technologies average salary is $-, median salary is $- with a salary range from $- to $-.
Adherex Technologies salaries are collected from government agencies and companies. Each salary is associated with a real job position. Adherex Technologies salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
-
Average
-
Median
-
High
-
Total 0 Adherex Technologies Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Adherex Technologies Salaries (May 25, 2016)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

Adherex Technologies salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Adherex Technologies Information
  • Adherex Technologies Inc
  • Industry: BioTech/Drugs
  • City: Research Triangle Park, NC
  • Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Our mission is to become an industry leader in meeting distinct, unmet or underserved medical needs in cancer.We currently have four products in the clinical stage of developing including ExherinTM, Adherex's lead biotechnology compound, and STS, a drug that protects against disabling hearing loss associated with platinum-based anticancer agents. We are systematically advancing our compounds through pre-clinical and clinical development with the intention that any early revenues from our specialty pharmaceuticals pipeline would be applied to the further development of our biotechnology platform.With